This is a 24 week, multicentre, prospective, randomized, controlled, parallel-designed (1:1)
pilot study.The study will compare glycemic variability in patients treated with insulin
glargine U300/ml insulin versus conventional (NPH) insulin using a self titration
algorithm.50 type 2 diabetes patients who are newly started on insulin will be recruited.
They will be randomly allocated to either insulin glargine U300 or NPH insulin for 26 weeks.
All subjects will follow a insulin-self titration algorithm. The study will consist of 9
visits over 26 weeks. Blood glucose variability will be collected by CGM for 7 consecutive
days at baseline (week -1) and at week 24.Secondary endpoints other than data on glycemic
variability, including HbA1c, fasting plasma glucose, inflammatory markers will be measured
during three periods (week 0, week 12 and week 24).